甲磺酸伏美替尼一线治疗1例EGFR 20号外显子插入突变肺腺癌患者

随着基因组学、蛋白组学和分子生物检测技术的不断创新,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗模式逐渐多样化,已经从传统的化疗逐渐过渡到免疫治疗及靶向治疗.其中,以靶向酪氨酸激酶通路为靶点的分子肿瘤标志物在临床中发挥着越来越重要的作用.针对NSCLC患者表皮生长因子受体(epidermal growth factor receptor,EGFR)突变阳性,现阶段市面上已经有众多一线治疗药物上市,且均有较为明显的治疗效果.在中国患者中EGFR常见的变异位点位于19、20和21号外显子上,其中19和21号外显子突变是较为常见的突变类型,除此以外,EG...

Full description

Saved in:
Bibliographic Details
Published inZhongguo fei ai za zhi Vol. 27; no. 3; pp. 241 - 244
Main Authors 李正国, 魏婷, 曾多, 赵丽, 张建婷, 陈来秀
Format Journal Article
LanguageChinese
English
Published No. 154 Anshan Road, Heping District, Tianjin, PRC, 300052 733000 武威,甘肃省武威肿瘤医院呼吸内科 20.03.2024
Editorial board of Chinese Journal of Lung Cancer
Subjects
Case Report
20号外显子插入突变
甲磺酸伏美替尼
Exon 20 insertion mutation
Furmonertinib mesylate
肺肿瘤
表皮生长因子受体
Epidermal growth factor receptor
Lung neoplasms
Online AccessGet full text
ISSN1009-3419
1999-6187
DOI10.3779/j.issn.1009-3419.2024.102.11

Cover

Abstract 随着基因组学、蛋白组学和分子生物检测技术的不断创新,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗模式逐渐多样化,已经从传统的化疗逐渐过渡到免疫治疗及靶向治疗.其中,以靶向酪氨酸激酶通路为靶点的分子肿瘤标志物在临床中发挥着越来越重要的作用.针对NSCLC患者表皮生长因子受体(epidermal growth factor receptor,EGFR)突变阳性,现阶段市面上已经有众多一线治疗药物上市,且均有较为明显的治疗效果.在中国患者中EGFR常见的变异位点位于19、20和21号外显子上,其中19和21号外显子突变是较为常见的突变类型,除此以外,EGFR突变还有一种亚型,被称为EGFR 20号外显子插入(EGFR exon 20 insertion,EGFR 20ins)突变.我们针对1例EGFR20ins突变肺腺癌患者接受甲磺酸伏美替尼治疗进行总结,以期为临床诊疗提供有效借鉴.
AbstractList 随着基因组学、蛋白组学和分子生物检测技术的不断创新，晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的治疗模式逐渐多样化，已经从传统的化疗逐渐过渡到免疫治疗及靶向治疗。其中，以靶向酪氨酸激酶通路为靶点的分子肿瘤标志物在临床中发挥着越来越重要的作用。针对NSCLC患者表皮生长因子受体（epidermal growth factor receptor, EGFR）突变阳性，现阶段市面上已经有众多一线治疗药物上市，且均有较为明显的治疗效果。在中国患者中EGFR常见的变异位点位于19、20和21号外显子上，其中19和21号外显子突变是较为常见的突变类型，除此以外，EGFR突变还有一种亚型，被称为EGFR 20号外显子插入（EGFR exon 20 insertion, EGFR 20ins）突变。我们针对1例EGFR 20ins突变肺腺癌患者接受甲磺酸伏美替尼治疗进行总结，以期为临床诊疗提供有效借鉴。
随着基因组学、蛋白组学和分子生物检测技术的不断创新,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗模式逐渐多样化,已经从传统的化疗逐渐过渡到免疫治疗及靶向治疗.其中,以靶向酪氨酸激酶通路为靶点的分子肿瘤标志物在临床中发挥着越来越重要的作用.针对NSCLC患者表皮生长因子受体(epidermal growth factor receptor,EGFR)突变阳性,现阶段市面上已经有众多一线治疗药物上市,且均有较为明显的治疗效果.在中国患者中EGFR常见的变异位点位于19、20和21号外显子上,其中19和21号外显子突变是较为常见的突变类型,除此以外,EGFR突变还有一种亚型,被称为EGFR 20号外显子插入(EGFR exon 20 insertion,EGFR 20ins)突变.我们针对1例EGFR20ins突变肺腺癌患者接受甲磺酸伏美替尼治疗进行总结,以期为临床诊疗提供有效借鉴.
Abstract_FL With the continuous innovation of genomics,proteomics and molecular biological detection technol-ogy,the treatment of non-small cell lung cancer(NSCLC)has changed from traditional chemotherapy to immunotherapy and targeted therapy.Among them,molecular tumor markers targeting tyrosine kinase pathways play more important roles in clinical practice.For advanced NSCLC patients with positive epidermal growth factor receptor(EGFR)mutations,there are many first-line drugs on the market and they could bring significant efficacy,thus completely subverting the treatment pattern of advanced NSCLC.Common mutations of EGFR in Chinese patients are located on exons 19,20 and 21,of which exons 19 and 21 mutations are the more common types.Besides,there is also a subtype of EGFR mutations,known as EGFR 20 exon insertion(EGFR 20ins)mutation.The authors summarized the treatment of a lung adenocarcinoma patient with EGFR 20ins mutation accepting Furmonertinib mesylate,in order to provide effective references for clinical diagnosis and treatment.
Author 曾多
李正国
赵丽
陈来秀
魏婷
张建婷
AuthorAffiliation 733000 武威,甘肃省武威肿瘤医院呼吸内科
AuthorAffiliation_xml – name: 733000 武威,甘肃省武威肿瘤医院呼吸内科
Author_FL Ting WEI
Laixiu CHEN
Duo ZENG
Zhengguo LI
Li ZHAO
Jianting ZHANG
Author_FL_xml – sequence: 1
  fullname: Zhengguo LI
– sequence: 2
  fullname: Ting WEI
– sequence: 3
  fullname: Duo ZENG
– sequence: 4
  fullname: Li ZHAO
– sequence: 5
  fullname: Jianting ZHANG
– sequence: 6
  fullname: Laixiu CHEN
Author_xml – sequence: 1
  fullname: 李正国
– sequence: 2
  fullname: 魏婷
– sequence: 3
  fullname: 曾多
– sequence: 4
  fullname: 赵丽
– sequence: 5
  fullname: 张建婷
– sequence: 6
  fullname: 陈来秀
BookMark eNpVkMFLAkEYxYcoKq3_oUPQabf5ZnZ2d04RUhYIQXlfZtdZU2oVN4s8leCpyIgwo6N1CYLwkpjoP-Pu2n_RhnXo9N7jffz4eAk065U8idAqYJUaBl8vqgXf91TAmCtUA64STLQ4EhVgBi0C51zRwTRmY_93s4ASvl_EWCecavNogZqMY-DmIjqI7rtRp__V6I0HzWh4Ez6NgvfBuHcR9Udh9zNqPcB4eLWV3t5fIThofgTPrbA9DN5uw-Zd0HiJXi-DZntS708a_ejxOqx3JheNJTTniiNfLv9qEmW3t7KpHSWzl95NbWaUsmkSxXEIMXVhEHB0ZsceXJAakwzcnA2E6y6TMmfrYHBpACdSagIYcxjNMVujNk2ijSm2XLWPZc6R3klFHFnlSuFYVM6tkihY_xuvcGjlS6cWxLuQmBgT1qaEM-G5wstbxVK14sUvW7W8K2q1n2UxxUDoN1enimg
ContentType Journal Article
Copyright Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
版权所有 © 2024《中国肺癌杂志》编辑部 Copyright © 2024, Chinese Journal of Lung Cancer. 2024 Chinese Journal of Lung Cancer
Copyright_xml – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved.
– notice: 版权所有 © 2024《中国肺癌杂志》编辑部 Copyright © 2024, Chinese Journal of Lung Cancer. 2024 Chinese Journal of Lung Cancer
DBID 2B.
4A8
92I
93N
PSX
TCJ
5PM
DOI 10.3779/j.issn.1009-3419.2024.102.11
DatabaseName Wanfang Data Journals - Hong Kong
WANFANG Data Centre
Wanfang Data Journals
万方数据期刊 - 香港版
China Online Journals (COJ)
China Online Journals (COJ)
PubMed Central (Full Participant titles)
DatabaseTitleList

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitle_FL First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion
EISSN 1999-6187
EndPage 244
ExternalDocumentID PMC11002192
zgfazz202403012
GroupedDBID ---
-05
04C
29R
2B.
2WC
4A8
5GY
5VS
6PF
92F
92I
93N
AAWTL
ABUWG
ACGFS
AFKRA
ALMA_UNASSIGNED_HOLDINGS
BENPR
BPHCQ
BVBZV
C1A
CCEZO
CCPQU
CIEJG
CW9
DIK
E3Z
EBD
EIHBH
EMOBN
EOJEC
F5P
GROUPED_DOAJ
HYE
IPNFZ
KQ8
KWQ
OBODZ
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PMFND
PQQKQ
PROAC
PSX
RIG
RNS
RPM
TCJ
TGQ
U1G
U5O
5PM
OVT
PUEGO
ID FETCH-LOGICAL-p882-cc2286a721c65b2281f1e45e51fdb1296f5eedb6179e7192ee4a155c53d5b43b3
ISSN 1009-3419
IngestDate Tue Sep 30 17:09:35 EDT 2025
Thu May 29 03:56:18 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 3
Keywords 20号外显子插入突变
甲磺酸伏美替尼
Exon 20 insertion mutation
Furmonertinib mesylate
肺肿瘤
表皮生长因子受体
Epidermal growth factor receptor
Lung neoplasms
Language Chinese
English
License This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p882-cc2286a721c65b2281f1e45e51fdb1296f5eedb6179e7192ee4a155c53d5b43b3
OpenAccessLink http://dx.doi.org/10.3779/j.issn.1009-3419.2024.102.11
PMID 38590198
PageCount 4
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_11002192
wanfang_journals_zgfazz202403012
PublicationCentury 2000
PublicationDate 20240320
PublicationDateYYYYMMDD 2024-03-20
PublicationDate_xml – month: 3
  year: 2024
  text: 20240320
  day: 20
PublicationDecade 2020
PublicationPlace No. 154 Anshan Road, Heping District, Tianjin, PRC, 300052
PublicationPlace_xml – name: No. 154 Anshan Road, Heping District, Tianjin, PRC, 300052
PublicationTitle Zhongguo fei ai za zhi
PublicationTitle_FL Chinese Journal of Lung Cancer
PublicationYear 2024
Publisher 733000 武威,甘肃省武威肿瘤医院呼吸内科
Editorial board of Chinese Journal of Lung Cancer
Publisher_xml – name: 733000 武威,甘肃省武威肿瘤医院呼吸内科
– name: Editorial board of Chinese Journal of Lung Cancer
SSID ssj0062934
ssib002262905
ssib044765436
ssib001103766
ssib038074678
ssib051369142
Score 2.4074883
Snippet 随着基因组学、蛋白组学和分子生物检测技术的不断创新,晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的治疗模式逐渐多样化,已经从传统的化疗逐渐过渡到免疫治疗及靶...
随着基因组学、蛋白组学和分子生物检测技术的不断创新，晚期非小细胞肺癌（non-small cell lung cancer, NSCLC）的治疗模式逐渐多样化，已经从传统的化疗逐渐过渡到免疫治...
SourceID pubmedcentral
wanfang
SourceType Open Access Repository
Aggregation Database
StartPage 241
SubjectTerms Case Report
Title 甲磺酸伏美替尼一线治疗1例EGFR 20号外显子插入突变肺腺癌患者
URI https://d.wanfangdata.com.cn/periodical/zgfazz202403012
https://pubmed.ncbi.nlm.nih.gov/PMC11002192
Volume 27
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
journalDatabaseRights – providerCode: PRVAFT
  databaseName: Open Access Digital Library
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: KQ8
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html
  providerName: Colorado Alliance of Research Libraries
– providerCode: PRVAON
  databaseName: DOAJ Directory of Open Access Journals
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DOA
  dateStart: 20080101
  isFulltext: true
  titleUrlDefault: https://www.doaj.org/
  providerName: Directory of Open Access Journals
– providerCode: PRVBFR
  databaseName: Free Medical Journals - Free Access to All
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: DIK
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: http://www.freemedicaljournals.com
  providerName: Flying Publisher
– providerCode: PRVHPJ
  databaseName: ROAD: Directory of Open Access Scholarly Resources
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssib044765436
  issn: 1009-3419
  databaseCode: M~E
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://road.issn.org
  providerName: ISSN International Centre
– providerCode: PRVAQN
  databaseName: PubMed Central
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: RPM
  dateStart: 20100101
  isFulltext: true
  titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/
  providerName: National Library of Medicine
– providerCode: PRVPQU
  databaseName: East & South Asia Database
  customDbUrl:
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: false
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BVBZV
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://search.proquest.com/eastsouthasia
  providerName: ProQuest
– providerCode: PRVPQU
  databaseName: ProQuest Central
  customDbUrl: http://www.proquest.com/pqcentral?accountid=15518
  eissn: 1999-6187
  dateEnd: 99991231
  omitProxy: true
  ssIdentifier: ssj0062934
  issn: 1009-3419
  databaseCode: BENPR
  dateStart: 19980101
  isFulltext: true
  titleUrlDefault: https://www.proquest.com/central
  providerName: ProQuest
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR3LahRBsIkJBi_iE-Mj7CFzCrvO9Ly6jzObiUFIkBght2WeiZc16AZhTzGwJ8UVkRjxGL0IguRi2ITkZ7I78S-s6umdnU3EFyzDUF1VXY_pqere7hpCpiI7jK0o4eWYxbh0E9My55FZDlXOmB6FRuDj0sD8gjX3yLi_bC6PnNsv7FpabwSVsPnLcyX_41WAgV_xlOw_eDZnCgC4B__CFTwM17_yseLZCjcUl-KNoyuuo3hcYabiMsUDeFVhs9jkegrzFM9SuKu4AAEEFVsRh-FeB8RxRJOF3FxXcAZ8WxNIQO9692YXp6mK1MDVtfHGMRALGTNEQsiMwlWEAA6nAhmAphDQgbRVkgO-Bz1TITITIjuiTxC_KsgpKuQJ6bKv7fRTaCk1dASsUKGZAqsCBz6DQNQVusujbb9FmAN4YCeSzQCFYwsThnI4qDpE7PY1Bd2dQQsYwMRfJp3kJpdTqIH7yaiaDwBb1yFITPdlsAQ_huahVenU3EJMF5CqMN4ZfKm6cDOQgFBo4KpwIUdjOMIGXBP-NtE5-HAAjoVWR7cAoVaITfg_FpbfKwavrLCCHKR6MRJl9cRkUkOzIpun4yVWmxTxEjuo5B1U0DBY1KMiA-FwRfLmSuI3m4iD82nIf8YohFR1lIy53sKDxUE2jmdQi6sD1KJ8EF7wUwcQpvPXv2HYeNA5xzc13eKakVeDA-Jsk0hfzHEyJXW4-zsNzm53Pv_cryd-faWQSS5dIhflFLDkZOP5Mhlprl4h4_Nyk8tV8jB9t5vudH609o4P2unh697Ho-63g-O9jbRz1NvdT7fea8eHL3E4lqjabX_vftrqbR92v77ptd92W5_TLy-67e2Tzc5Jq5N-eNXb3DnZaF0jS7PeUnWuLL99Ul7DOW8YUsos36ZaaJkB3GuJFhtmbGpJFECKbiUmJLcBTD94bMMkLY4NH2YGoalHZmDogX6djNaf1OMbpMQDHuBWDyNigZGokR9Huu7Hmg4cbWYFE4QNmae2lpW5qWHh-eGW-uNVUYAey0xCpkMnSElasibfis9qpx6Om39GuUUuDAbibTLaeLoe34FMvxFMyidqUqyU_QSepc0A
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E7%94%B2%E7%A3%BA%E9%85%B8%E4%BC%8F%E7%BE%8E%E6%9B%BF%E5%B0%BC%E4%B8%80%E7%BA%BF%E6%B2%BB%E7%96%971%E4%BE%8BEGFR+20%E5%8F%B7%E5%A4%96%E6%98%BE%E5%AD%90%E6%8F%92%E5%85%A5%E7%AA%81%E5%8F%98%E8%82%BA%E8%85%BA%E7%99%8C%E6%82%A3%E8%80%85&rft.jtitle=%E4%B8%AD%E5%9B%BD%E8%82%BA%E7%99%8C%E6%9D%82%E5%BF%97&rft.au=%E6%9D%8E%E6%AD%A3%E5%9B%BD&rft.au=%E9%AD%8F%E5%A9%B7&rft.au=%E6%9B%BE%E5%A4%9A&rft.au=%E8%B5%B5%E4%B8%BD&rft.date=2024-03-20&rft.pub=733000+%E6%AD%A6%E5%A8%81%2C%E7%94%98%E8%82%83%E7%9C%81%E6%AD%A6%E5%A8%81%E8%82%BF%E7%98%A4%E5%8C%BB%E9%99%A2%E5%91%BC%E5%90%B8%E5%86%85%E7%A7%91&rft.issn=1009-3419&rft.volume=27&rft.issue=3&rft.spage=241&rft.epage=244&rft_id=info:doi/10.3779%2Fj.issn.1009-3419.2024.102.11&rft.externalDocID=zgfazz202403012
thumbnail_s http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Fzgfazz%2Fzgfazz.jpg